tbuckley/cabot-search huggingface dataset:
SP0142 Developing Eular Recommendations for the Use of Imaging in Spondyloarthritis Clinical Practice: Background and Process
Authors: P. Mandl
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> Reflecting the perceived need for developing evidence-based recommendations on the use of imaging of the joints in the clinical management of spondyloarthritis (SpA) a European League Against Rheumatism (EULAR) convened a task force comprised of an expert group of 21 rheumatologists, radiologists and methodologists from 11 countries. The objectives of the task force were to formulate key clinical research questions relating to the role of imaging in both axial and peripheral SpA, to identify and critically appraise the available evidence, and to generate recommendations based on both evidence and expert opinion. Evaluated imaging modalities included conventional radiography, ultrasound, magnetic resonance imaging, computed-, positron emission- and single photon emission computed tomography, dual-emission x-ray absorptiometry and scintigraphy. Twelve research questions were generated using a process of discussion and consensus and a total of three systematic literature searches of articles were performed using MEDLINE and EMBASE databases. In addition the abstract archives of relevant international rheumatology and radiology meetings as well as the bibliographies of included papers were hand searched for evidence of other studies for inclusion. Titles and abstracts of all citations identified were screened, and potentially relevant articles were reviewed in full text using predetermined inclusion and exclusion criteria. A total of 7550 references were identified in the search process, from which 158 studies were finally included in the systematic reviews. Quality assessment of the included studies was performed using the QUADAS-2 tool. The results were presented to the taskforce members who then developed 10 recommendations, encompassing the full spectrum of imaging in making a diagnosis of axial or peripheral SpA, monitoring inflammation and damage, predicting outcome, response to treatment, and detecting spinal fractures and osteoporosis. The strength of each recommendation (SOR) was assessed by the taskforce members using a visual analogue scale and was generally very high (mean 8.9-9.5). <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6280
PWE-114 The Ibd-control Questionnaire: Multi-centre Validation Plus Evaluation In Routine Care
Authors: T Gledhill, E Brown, B Collins, S Subramanian, A Bassi, K Bodger
Journal: Gut (2014)

<h3>Introduction</h3> Routine capture of reliable, patient-centred health status measures for IBD has not become part of standard practice. The IBD-Control questionnaire is a short (13 item), generic patient-reported outcome measure which we developed to support routine care.<sup>1</sup> <h3>Methods</h3> To further define performance in varied settings, we undertook: <b>(A)</b> A prospective study at an inner city teaching hospital and a DGH, to show reproducibility of psychometric properties. Clinic patients completed IBD-Control and the local IBD team recorded activity index, global physician assessment and treatment. <b>(B)</b> A prospective endoscopic study, with IBD-Control prior to endoscopy and Mayo score of mucosa. IBD teams were blinded to questionnaires. <b>(C)</b> A service evaluation in our unit, auditing implementation of IBD-Control to support a new virtual (telephone) clinic – a case study on integrating PROMs into routine care. <h3>Results</h3> 113 IBD-Control questionnaires returned to date. <h3>Patients</h3> Age, mean [sd]: 50 [16] yrs; Female: 54%; UC: 73%; Disease duration, mean [sd]: 7.5 [7.7] yrs. Global Physician Assessment: Inactive 48.3%; Mild 41.3%; Moderate 10.3%; Severe 0%. Summary scores, mean [sd]: IBD-Control-8 (range: 0–16): 11.7 [5.2]; IBD-Control-VAS (range: 0–100): 73.5 [76.1]. Psychometric properties: <i>Completion rate</i>: 93–94% per item; Strong correlation between the 2 summary scores: IBD-Control-8 vs IBD-Control-VAS, r = 0.83; <i>Validity</i> of summary scores, IBD-Control-8 [IBD-Control-VAS]: (1) <i>Simple Clinical Colitis Activity Index</i>, r = –0.77 [–0.72]; (2) <i>Harvey Bradshaw Index</i>, r = –0.91 [–0.78] (3) <i>Mayo Score</i>, r = –0.64 [–0.69]; (3) <i>Global Physician Assessment</i>, mean scores differed significantly across categories for both scores (inactive &gt; mild &gt; moderate; p &lt; 0.01, ANOVA). Service Evaluation: 64 ‘delayed follow-up or DNA’ patients invited for postal return of PROM then 4–6 wk review, with 59% return rate (‘active disease’ indicated in 10%). Telephone consultation in 63%. Unplanned care occurred in 2 respondents within 30 days, both with IBD-Control indicative of active disease. <h3>Conclusion</h3> IBD-Control has strong measurement properties and is easy to administer. Our experience of integrating IBD-Control into non-face-to-face follow-up clinics suggests that using a validated PROM to support care is acceptable to patients and achievable. <h3>Reference</h3> Bodger K <i>et al</i>. Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-Control questionnaire. <i>Gut </i>2013;published online October 9:2013 [ahead of print] <h3>Disclosure of Interest</h3> None Declared.
Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease
Authors: Arman Qamar, Deepak L. Bhatt
Journal: Circulation (2016)

C ase Presentation: A 68-year-old woman with hypertension, diabetes mellitus, and congestive heart failure presented to the emergency department with palpitations.On physical examination, her heart rate was 130 bpm and irregularly irregular, her blood pressure was 120/70 mm Hg, and she weighed 60 kg.The ECG demonstrated atrial fibrillation (AF) with a rapid ventricular rate.Laboratory evaluation was remarkable for a serum creatinine of 1.3 mg/dL.Her symptoms resolved with heart rate control.
AB0327 Patterns of magnetic resonance imaging of the foot in rheumatoid arthritis: which joints are most frequently involved?
Authors: P. Sewerin, C. Buchbender, A. Scherer, F. Miese, R. Brinks, W. Hans-Jörg, G. Antoch, M. Schneider, B. Ostendorf
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To investigate patterns of inflammatory MRI pathologies of the fore- and midfoot in rheumatoid arthritis (RA) and early RA (ERA) and their changes under therapy. <h3>Methods</h3> In this prospective study MRI data of the foot of 39 RA patients (29 female, 10 male; age: 54±13 years; disease duration: 35±37 months; baseline DAS28: 3.0±2.0; medication: 29 DMARD, 1 biological, 9 symptomatic or non specific treatment) were evaluated for synovitis in 314 joints, bone marrow edema and erosions according to RAMRIS criteria in a total of 585 joints. The change in joint pathology intensity was evaluated on follow-up MRI (time of follow-up: 8±4 months) in 25 patients. <h3>Results</h3> Inflammation was generally more frequent in the metatarsophalangeal (MTP) joints (221/292; 76%) than in the proximal metatarsal (47/292; 16%) and tarsal bones (24/292; 8%). The overall most frequently involved joints of the foot were MTP 5 (51/292; 18%) and 1 (49/292; 17%). Change under therapy was most frequently seen in the MTP 1 joint. Progress of inflammation in the MTP 1 was more frequently found in ERA patients than in patients with established RA (disease duration &gt;12 months) (p=0.002). <h3>Conclusions</h3> In RA the MTP joints, primarily MTP 5 and 1, are the predominant sites of inflammatory MRI pathologies of the foot. A change of inflammatory activity under therapy can be most frequently noted in the MTP 1 joint. This information might be helpful to improve effectiveness of MRI-controlled therapy approaches and clinical trials. <h3>Disclosure of Interest</h3> None Declared
T-Cell Receptor Gene Rearrangements as Clinical Markers of Human T-Cell Lymphomas
Authors: Virginia Bertness, Ilan Kirsch, Gregory Hollis, Bruce Johnson, Paul A. Bunn
Journal: New England Journal of Medicine (1985)

The ability to detect immunoglobulin-gene rearrangements has proved useful in confirming diagnoses of suspected B-cell lymphomas and in establishing their monoclonality. By analogy, we employed a cloned DNA probe for the beta chain of the T-cell receptor gene to determine whether gene rearrangements were present in human T-cell neoplasms representing various stages of T-cell development. Gene rearrangements were present in all cases of T-cell disorders except a single case of T gamma lymphocytosis, a disorder that has not been proved to be a clonal T-cell neoplasm. A germline gene configuration was present in all patients with non-T-cell neoplasms and in normal tissues from patients with T-cell lymphoma. The probe promises to be useful for confirming the pathological an immunologic diagnosis in difficult cases of T-cell disorders and for assessing the extent of disease.
Case 38-1998
Authors: Stuart M. Levitz, Eugene J. Mark
Journal: New England Journal of Medicine (1998)

Presentation of CaseA 19-year-old man was admitted to the hospital because of a febrile illness.The patient had been well until five weeks earlier, when a dry cough developed. Two weeks later, bouts of fever and chills began, and the cough became productive of greenish sputum. The patient had a weight loss of 9 kg. Two days before admission, radiographs of the chest (Figure 1) showed patchy opacities in the left lower lobe that were consistent with the presence of pneumonia and left hilar, possibly right hilar, and right paratracheal lymphadenopathy. Laboratory tests were performed (Table 1 and Table 2). Tuberculin . . .
Abstract B72: A computational approach integrating proteomic, transcriptional, and interactome data for discovery of cellular signaling networks
Authors: Shao-shan Carol Huang, Ernest Fraenkel
Journal: Cancer Research (2009)

Abstract Cellular signaling and transcription are tightly integrated processes that have profound effects on every stage of tumor development and growth. Although there are now a variety of high-throughput methods for studying these processes, our knowledge of them remains fragmentary. Typically, the vast majority of hits identified by transcriptional, proteomic and genetic assays lie outside of the expected pathways. These unexpected components of the cellular response are often the most interesting, as they can provide new insights into biological processes and potentially reveal new therapeutic approaches. However, they are also the most difficult to interpret. We present a technique, based on the Steiner tree algorithm, that uses previously reported protein-protein interactions to determine how these hits are organized into functionally coherent pathways, revealing many components of the cellular response that are not readily apparent in the original data. Applied to simultaneously to phosphoproteomic and transcriptional profiling data for the yeast pheromone response, it identifies changes in diverse cellular processes that extend far beyond the expected pathways. We expect our current analysis of the experimental data from epidermal growth factor (EGF) signaling network in non-tumorigenic and tumorigenic cells will shed light on the regulation of cellular processes at the global level and the consequences of oncogenic mutations on signaling and transcription. Citation Information: Cancer Res 2009;69(23 Suppl):B72.
EXPERIMENTAL IMMUNOHISTOCHEMICAL STUDY ON PERSISTENT VASCULAR REMODELING RELATED TO DEVELOPMENT OF ARTERIOSCLEROSIS OR ATHEROSCLEROSIS IN CHRONIC KAWASAKI DISEASE PATIENTS
Authors: Kenji Hamaoka, Maiko Fujii, Ayako Yoshioka, Yuki Kuchitsu, Akiko Okamoto, Chinatsu Suzuki, Tomoyo Yahata, Akihiro Nakamura, Kazuyuki Ikeda
Journal: Journal of the American College of Cardiology (2015)
Abstract 3655: c-JunNH2-teminal kinase 1 plays a crucial role in vitamin D-mediated cancer cellmaturation through interacting with vitamin D receptor.
Authors: Qi Shi, Xiuli Bi, Wenfeng Fang, Dong Hu, Zhiguo Chen, Huali Dong, Wancai Yang, Wancai Yang
Journal: Cancer Research (2013)

Abstract Vitamin D is chemopreventive against colorectal carcinogenesis in vivo and in vitro. The protective effects of vitamin D against colonic carcinogenesis are most probably mediated through the vitamin D receptor (VDR). When bound to the hormonally active form of vitamin D, 1,25(OH)2-D3, VDR transactivates genes that inhibit proliferation, or promote differentiation and apoptosis. Previous studies showed that stress-activated protein kinase JNKs (c-Jun NH2-terminal kinases) and p38 cooperated to activate VDR and increase vitamin D3-dependent growth inhibition in breast cancer cells. To determine whether vitamin D-mediated maturation is associated with JNK1 and VDR in colorectal cancer cells, we treated the human colon cancer cell HT29 with 1,25(OH)2-D3, and found that 1,25(OH)2-D3 significantly inhibited cell proliferation and induced apoptosis, which was associated with induction of phosphorylated JNK1 (p-JNK1) and p21,p27, which was also associated with increased the expression of PARP and cleaved Caspase 3. In the JNK1 knockout mouse model in which tumor spontaneously formed in intestinal tract, we found that VDR was significantly reduced or not expressed in mouse intestinal epithelial cells, compared to those in the wild-type mice. Further, we found that VDR transcriptional activity was lower in JNK1-/- mouse embryonic fibroblast cells (MEFs), assayed by transfection with VDR-element-Luc reporter. When the JNK1-/- MEFs were treated with calcitriol, the induced of VDR transcriptional activity was also attenuated, compared to that in JNK1+/+ MEFs. Moreover, increasing expression of activated JNK1 by transfection with pcDNA3-Flag-MKK7 (activated JNK1) in HT29 colon cancer cells, VDR-element-Luc was significantly increased, and VDR expression levels were also increased. Finally, we co-transfected HEK239 cells with pcDNA3-HA-VDR and pcDNA3-Flag-MKK7 plasmids and conducted co-immunoprecipitation assay, we found that VDR was physically binding to JNK1. Taken together, JNK1 interacted with VDR and affected VDR at transcriptional and translational levels. Thus, the status of JNK1 may play a critical role in vitamin D-medicated cancer prevention through modulating vitamin D receptor. Whether JNK1 affects VDR polymorphisms and then influences cancer prevention efficacy of vitamin D is under further investigation. *Supported by National Natural Science Foundation Of China (81272251) Citation Format: Qi Shi, Xiuli Bi, Wenfeng Fang, Dong Hu, Zhiguo Chen, Huali Dong, Wancai Yang, Wancai Yang. c-JunNH2-teminal kinase 1 plays a crucial role in vitamin D-mediated cancer cellmaturation through interacting with vitamin D receptor. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3655. doi:10.1158/1538-7445.AM2013-3655
Combined Hepatocellular Carcinoma and Cholangiocarcinoma With High F-18 Fluorodeoxyglucose Positron Emission Tomographic Uptake
Authors: SUSUMU SHIOMI, NOBUMITSU SASAKI, DAICHI KAWASHIMA, HISATO JOMURA, TAKASHI FUKUDA, TETSUO KUROKI, KOUICHI KOYAMA, JOJI KAWABE, HIRONOBU OCHI
Journal: Clinical Nuclear Medicine (1999)

A 34-year-old woman was hospitalized for further evaluation of a space-occupying lesion in the liver. Ga-67 SPECT showed increased accumulation of isotope in the tumor periphery. Fluorine-18 Fluorodeoxygluclose (F-18 FDG) positron emission tomography (PET) revealed a ring-like accumulation of isotope at the tumor periphery, and the standardized uptake value was 8 to 11. A mixed type of combined hepatocellular carcinoma and cholangiocarcinoma was diagnosed.
Abstract 4291: Imetelstat, a telomerase inhibitor in phase I trials in solid tumor and hematological malignancies, has broad activity against multiple types of cancer stem cells
Authors: Immanual Joseph, William Matsui, Caterina A M LaPorta, Uri Tabori, Harley Kornblum, Brittney-Shea Herbert, Calvin Harley, Robert J. Tressler
Journal: Cancer Research (2010)

Abstract Numerous studies show that multiple tumor types have rare subpopulations of cells that are initiators of tumor growth, recurrence, and are implicated in tumor metastasis formation. Because of their clonogenic potential, these cells are referred to as tumor initiating cells (TICs) or cancer stem cells. TICs express ABC transporters and can reside in the host in a quiescent state within their preferred niche, which contributes to their resistance to therapies that are effective against bulk tumor cells. Patients having significant objective responses often develop recurrent resistant disease that is thought to be due to TIC outgrowth, and this is thought to contribute to a lack of clinically durable responses. Therefore agents targeting TICs should be included in current therapeutic strategies to assure more effective disease control in patients. Telomerase activation is a common phenotype for the majority of cancers and is essential for maintaining their immortal phenotype. Most tumors having elevated telomerase activity also have shorter telomere lengths than their normal tissue counterparts, and these characteristics make telomerase a promising therapeutic target for cancer. Tumor initiating cells, while distinct from the bulk tumor cell population, share the common traits of increased telomerase activity and relatively short telomeres, suggesting that inhibiting telomerase would be an effective modality for targeting these cells across multiple tumor types. Imetelstat is a potent and specific competitive inhibitor of telomerase currently in phase I clinical trials in solid tumor and hematological malignancies. We have carried out in vitro and in vivo studies demonstrating that imetelstat inhibits telomerase and is effective in targeting TICs from myeloma, melanoma, breast, pancreatic, pediatric glioma, neuroblastoma, prostatic, lung and glioblastoma multiforme tumor types. Our data show that while treatment of TICs with imetelstat is effective, the mechanisms of TIC inhibition may vary depending on the tumor type, and can include antiproliferative effects, induction of apoptotosis or senescence, terminal differentiation, and inhibition of clonogenicity in vitro, as well as inhibition of tumor engraftment and spontaneous metastasis formation in vivo. In summary, imetelstat, a first in class telomerase inhibitor currently in clinical trials, is a promising agent for targeting TICs with broad activity against multiple cancer stem cell types, but the mechanism of inhibition of TICs may vary depending on the specific tumor type. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4291.
THU0323 Subsettting Proliferative Lupus Nephritis According to the ISN/RPS Classification Does not Provide Valuable Prognostic Information
Authors: J. Vandepapelière, S. Aydin, G. Depresseux, J.-P. Cosyns, M. Jadoul, F. A. Houssiau
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To evaluate, including through repeated renal biopsy, whether the different ISN/RPS classes of proliferative lupus nephritis (LN) have similar short- and long-term responses to immunosuppression and have distinct long-term prognosis. <h3>Methods</h3> Ninety-eight patients with new onset ISN/RPS proliferative (III, IV-S or IV-G) LN were diagnosed in our institution between 2001 and 2011. Their baseline renal parameters and their primary response to immunosuppressive therapy were compared, based on quarterly collected data during the first year. Long-term followup (mean 76 months) was also available, as well as repeated renal biopsy data, performed in 45 patients after a mean period of 30 months. Activity (range 0-42) and chronicity (range 0-6) indices were computed according to the Morel-Maroger scoring system. <h3>Results</h3> While baseline mean 24-h proteinuria was higher in Class IV-G patients (n=50) compared to Class III (n=25) and Class IV-S (n=23) and while baseline mean activity index was lower in Class III versus Class IV-S and Class IV-G, serum creatinine, serum albumin and 24-h proteinuria improved similarly over the first year in the 3 pathological classes. Morover, biochemical data collected at last followup did not differ, nor did the activity/chronicity index on repeated renal biopsy, nor the rate of end-stage renal disease or death. Percentages of patients treated with cyclophosphamide, mycophenolate mofetil and azathioprine were similar in the 3 pathological groups. <h3>Conclusions</h3> Long-term clinical and pathological prognosis of new-onset proliferative LN, can not be predicted by baseline subsetting according to the ISN/RPS classification. <h3>Disclosure of Interest</h3> None Declared
Coincidental Finding of Crossed Fused Renal Ectopia Detected on Bone Scintigraphy
Authors: CLAYTON J. FRATER, MONICA A. ROSSLEIGH
Journal: Clinical Nuclear Medicine (2000)

A 26-year-old man was examined for long-standing back pain, with a provisional diagnosis of sacroilitis or ankylosing spondylitis. A limited bone scan with SPECT was performed 2.5 hours after injection. Although the results were essentially normal, the right pelvic kidney was seen on both blood-pool images and delayed images, but the left kidney was seemingly absent. The patient noted that, after a sports-related trauma to the abdomen 10 years before, an intravenous urogram at the time showed a cross fused renal ectopia lying in the right iliac fossa, with two normal pelvicalyceal systems. Subsequently, the patient was advised to discontinue participating in contact sports.